NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal first quarter ended September 30, 2023, and provided a business update.
“We achieved strong revenue growth over the first quarter of fiscal 2024, maintaining the momentum we have built over the past several quarters,” commented Harry Simeonidis, President and Chief Executive Officer of Intelligent Bio Solutions Inc. “This growth is largely attributable to the increasing acceptance of our proprietary Intelligent Fingerprinting Drug Screening System by customers, which has translated to consistent sales and increased revenue. The sustained rising demand for our innovative screening product across a diverse number of industries demonstrates its versatility and its value as a faster, more efficient, and less-invasive drug screening solution for workplaces.”
“We expanded our market presence in South America while advancing our reach in existing markets. We are now focused on executing our plan to enter the U.S. market after receiving FDA guidance on a regulatory pathway for our Intelligent Fingerprinting Drug Screening Cartridge earlier this year,” Mr. Simeonidis added.
First Quarter & Recent Highlights:
First Fiscal Quarter Ended September 30, 2023, Financial Results
All amounts are expressed in U.S. dollars unless indicated otherwise. All authorized, issued, and outstanding stock and per share amounts reflect the 1-for-20 reverse stock split effected by the Company on February 9, 2023, unless indicated otherwise.
The Company’s combined revenue and government support income increased by 191% to $0.91 million for the first fiscal quarter ended September 30, 2023, including revenue from sales of goods of $0.8 million, compared to $0 in the first fiscal quarter ended September 30, 2022. The increase in revenue is due to the acquisition of Intelligent Fingerprinting Ltd (“IFP”) in October 2022 and the launch of its Intelligent Fingerprinting Drug Screening System in the Asia-Pacific region via Intelligent Bio Solutions (APAC) Pty Ltd.
Net loss attributable to INBS for the first fiscal quarter ended September 30, 2023 was $2.4 million, compared to a net loss of $1.2 million for the first fiscal quarter of the prior fiscal year. This increase is primarily driven by the combined results of operations after the acquisition of IFP offset by a recognition of fair value gain on revaluation of holdback Series C Preferred Stock during the current quarter of $131,250.
The Company ended the quarter with cash and cash equivalents of approximately $0.2 million. On October 4, 2023, subsequent to the quarter ended September 30, 2023, the Company raised approximately $4.378 million prior to deducting underwriting discounts and commissions and offering expenses via a registered underwritten public offering of the Company’s securities. Net proceeds to the Company, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $3.35 million.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (the "Company") (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. This hygienic, and cost-effective system is designed to screen for recent use of drugs commonly found in the workplace, including opioids, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its screening and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Cheryl Billson
Comma Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Valter Pinto
KCSA Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Intelligent Bio Solutions Inc. Condensed Consolidated Balance Sheets (Amounts in US$) | ||||||||
| September 30, 2023 (Unaudited) | June 30, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 186,401 | $ | 1,537,244 | ||||
| Accounts receivable, net | 567,510 | 293,861 | ||||||
| Inventories, net | 965,091 | 979,907 | ||||||
| Research and development tax incentive receivable | 559,588 | 498,758 | ||||||
| Other current assets | 413,305 | 552,791 | ||||||
| Total current assets | 2,691,895 | 3,862,561 | ||||||
| Property and equipment, net | 664,922 | 690,175 | ||||||
| Operating lease right-of-use assets | 471,532 | 546,475 | ||||||
| Intangible assets, net | 4,872,141 | 5,255,401 | ||||||
| TOTAL ASSETS | $ | 8,700,490 | $ | 10,354,612 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 3,628,797 | $ | 2,610,028 | ||||
| Current portion of operating lease liabilities | 227,414 | 223,447 | ||||||
| Current portion of deferred grant income | 2,240,929 | 2,338,057 | ||||||
| Current employee benefit liabilities | 406,964 | 358,942 | ||||||
| Current portion of notes payable | 341,834 | 353,211 | ||||||
| Total current liabilities | 6,845,938 | 5,883,685 | ||||||
| Employee benefit liabilities, less current portion | 27,732 | 24,902 | ||||||
| Operating lease liabilities, less current portion | 284,028 | 356,165 | ||||||
| Notes payable, less current portion | 306,234 | 402,862 | ||||||
| Total liabilities | 7,463,932 | 6,667,614 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity: | ||||||||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 2,330,399 shares issued and outstanding at September 30, 2023 and June 30, 2023, respectively | 23,304 | 23,304 | ||||||
| Treasury stock, at cost, 1,386 shares as of September 30, 2023 and June 30, 2023, respectively | (14 | ) | (14 | ) | ||||
| Additional paid-in capital | 46,158,763 | 46,158,763 | ||||||
| Accumulated deficit | (44,232,777 | ) | (41,807,573 | ) | ||||
| Accumulated other comprehensive loss | (593,512 | ) | (575,496 | ) | ||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 1,355,764 | 3,798,984 | ||||||
| Non-controlling interest | (119,206 | ) | (111,986 | ) | ||||
| Total shareholders’ equity | 1,236,558 | 3,686,998 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 8,700,490 | $ | 10,354,612 | ||||
| Intelligent Bio Solutions Inc. Condensed Consolidated Statements of Operations and Other Comprehensive Loss* (Unaudited) (Amounts in US$) | ||||||||
| Three Months Ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Revenue | $ | 796,094 | $ | - | ||||
| Cost of revenue (exclusive of amortization shown separately below) | (563,763 | ) | - | |||||
| Gross profit | 232,331 | - | ||||||
| Other income: | ||||||||
| Government support income | 109,871 | 311,320 | ||||||
| Operating expenses: | ||||||||
| Selling, general and administrative expenses | (2,457,060 | ) | (1,450,418 | ) | ||||
| Development and regulatory approval expenses | (103,947 | ) | (79,274 | ) | ||||
| Depreciation and amortization | (307,560 | ) | - | |||||
| Total operating expenses | (2,868,567 | ) | (1,529,692 | ) | ||||
| Loss from operations | (2,526,365 | ) | (1,218,372 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | (37,448 | ) | (1,065 | ) | ||||
| Realized foreign exchange loss | - | (2,247 | ) | |||||
| Fair value gain on revaluation of financial instrument | 131,250 | - | ||||||
| Interest income | 139 | 7,606 | ||||||
| Total other income | 93,941 | 4,294 | ||||||
| Net loss | (2,432,424 | ) | (1,214,078 | ) | ||||
| Net loss attributable to non-controlling interest | (7,220 | ) | (5,785 | ) | ||||
| Net loss attributable to Intelligent Bio Solutions Inc. | $ | (2,425,204 | ) | $ | (1,208,293 | ) | ||
| Other comprehensive loss, net of tax: | ||||||||
| Foreign currency translation loss | $ | (18,016 | ) | $ | (135,559 | ) | ||
| Total other comprehensive loss | (18,016 | ) | (135,559 | ) | ||||
| Comprehensive loss | (2,450,440 | ) | (1,349,637 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | (7,220 | ) | (5,785 | ) | ||||
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | $ | (2,443,220 | ) | $ | (1,343,852 | ) | ||
| Net loss per share, basic and diluted* | $ | (1.04 | ) | $ | (1.62 | ) | ||
| Weighted average shares outstanding, basic and diluted* | 2,330,399 | 744,495 | ||||||
| * | Common Stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated. | |
| Last Trade: | US$1.48 |
| Daily Change: | -0.04 -2.63 |
| Daily Volume: | 95,468 |
| Market Cap: | US$4.620M |
November 13, 2024 November 07, 2024 October 29, 2024 October 16, 2024 October 01, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
